CD274 and breast cancer: This calls again for targeting the PD-1 receptor in multimodal RT- and HT-based tumor therapies, rather than only PD-L1, as, additionally, the utility of PD-L1 as a predictive biomarker in most of the breast cancer subtypes remains elusive [64].